These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
13. The role of immunoprophylaxis in the reduction of disease attributable to respiratory syncytial virus. Meissner HC; Bocchini JA; Brady MT; Hall CB; Kimberlin DW; Pickering LK Pediatrics; 2009 Dec; 124(6):1676-9. PubMed ID: 19948632 [No Abstract] [Full Text] [Related]
14. [Experience of palivizumab in prophylaxis of respiratory syncytial viral infection in premature children with bronchopulmonary dysplasia]. Aliamovskaia GA; Keshinian ES Vestn Ross Akad Med Nauk; 2012; (12):30, 32-4. PubMed ID: 23530423 [TBL] [Abstract][Full Text] [Related]
15. Re: recommendation for the use of palivizumab as prophylaxis against respiratory syncytial virus in infants with congenital cardiac disease. Onuzo OC Cardiol Young; 2004 Aug; 14(4):466-7; author reply 467-9. PubMed ID: 15680062 [No Abstract] [Full Text] [Related]
17. Ethical considerations and rationale of the MAKI trial: a multicenter double-blind randomized placebo-controlled trial into the preventive effect of palivizumab on recurrent wheezing associated with respiratory syncytial virus infection in children with a gestational age of 33-35 weeks. Blanken M; Rovers M; Sanders E; Bont L Contemp Clin Trials; 2012 Nov; 33(6):1287-92. PubMed ID: 22820319 [TBL] [Abstract][Full Text] [Related]
18. Efficacy and optimization of palivizumab injection regimens against respiratory syncytial virus infection. Gutfraind A; Galvani AP; Meyers LA JAMA Pediatr; 2015 Apr; 169(4):341-8. PubMed ID: 25706618 [TBL] [Abstract][Full Text] [Related]